<DOC>
	<DOCNO>NCT01015560</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , MLN1202 , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . PURPOSE : This phase II trial study well MLN1202 work treat patient bone metastasis .</brief_summary>
	<brief_title>S0916 , MLN1202 Treating Patients With Bone Metastases</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess urinary n-telopeptide ( uNTX ) response anti-CCR2 monoclonal antibody MLN1202 patient bone metastasis . Secondary - To assess feasibility perform cross-disease site trial within Southwest Oncology Group . - To explore effect anti-CCR2 monoclonal antibody MLN1202 marker tumor cell proliferation , monocytes/macrophage trafficking , osteoclast maturation . - To estimate allele frequency define SNPs occur CCL2 CCR2 gene patient . OUTLINE : This multicenter study . Patients receive anti-CCR2 monoclonal antibody MLN1202 IV 1 hour day 1 , 15 , 29 absence disease progression unacceptable toxicity . Patients undergo urine blood sample collection baseline day 15 , 29 , 43 correlative biomarker polymorphism study . After completion study treatment , patient follow ≥ 30 day .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Radiographically document metastasis bone bone scan , xray , CT scan , MRI , PET scan within past 42 day Documentation progression metastatic disease serial scan require study entry No untreated progressive brain metastasis History brain metastasis allow provide treated remain control PATIENT CHARACTERISTICS : Zubrod performance status 02 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Must consent urine blood specimen submissions No concurrent uncontrolled illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement No known hypersensitivity antiCCR2 monoclonal antibody MLN1202 recombinant human antibody PRIOR CONCURRENT THERAPY : At least 14 day since prior radiotherapy recover ( ≤ grade 1 related toxicity ) At least 84 day since prior radionuclide therapy ( e.g. , strontium , samarium ) recover ( ≤ grade 1 related toxicity ) More 14 day since prior investigational agent , chemotherapeutic agent , anticancer agent Concurrent bisphosphonate therapy bone metastases allow provided treatment initiate ≥ 28 day study entry No initiation bisphosphonates study treatment Concurrent hormonal therapy ( e.g. , antiestrogens antiandrogens ) stable dos steroid cancer allow provide treatment initiate &gt; 14 day study entry No concurrent GCSF growth factor support</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>bone metastasis</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>